Pawankar Allergy Frontiers:Future Perspectives

1. Auflage 2009
ISBN: 978-4-431-99365-0
Verlag: Springer-Verlag
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 324 Seiten

When I entered the field of allergy in the early 1970s, the standard textbook was a few hundred pages, and the specialty was so compact that texts were often authored entirely by a single individual and were never larger than one volume. Compare this with Allergy Frontiers: Epigenetics, Allergens, and Risk Factors, the present s- volume text with well over 150 contributors from throughout the world. This book captures the explosive growth of our specialty since the single-author textbooks referred to above. The unprecedented format of this work lies in its meticulous attention to detail yet comprehensive scope. For example, great detail is seen in manuscripts dealing with topics such as “Exosomes, naturally occurring minimal antigen presenting units” and “Neuropeptide S receptor 1 (NPSR1), an asthma susceptibility gene.” The scope is exemplified by the unique approach to disease entities normally dealt with in a single chapter in most texts. For example, anaphylaxis, a topic usually confined to one chapter in most textbooks, is given five chapters in Allergy Frontiers. This approach allows the text to employ multiple contributors for a single topic, giving the reader the advantage of being introduced to more than one vi- point regarding a single disease.

Autoren/Hrsg.

Pawankar, Ruby

Inhaltsverzeichnis

1;Foreword;5
2;Foreword;7
3;Foreword;9
4;Preface;11
5;Contents;13
6;Contributors;15
7;Functional Genomics and Proteomics in Allergy Research;20
8;Bioinformatics in Allergy: A Powerful Tool Joining Science and Clinical Applications;38
9;Engineering Allergy Vaccines: Approaches Towards Engineered Allergy Vaccines;50
10;Reconstructing the Repertoire of Mite Allergens by Recombinant DNA Technology;67
11;Immunostimulatory (CpG) DNA-Based Therapies for the Treatment of Allergic Disease;83
12;Peptide-Based Therapeutic Vaccines for Allergic Diseases: Where Do We Stand?;96
13;NKT Ligand Conjugated Immunotherapy;108
14;Targeting Th2 Cells in Asthmatic Airways;120
15;Transgenic Rice for Mucosal Vaccine and Immunotherapy;165
16;Targeting STAT6 in Atopic Eczema/Dermatitis;183
17;Mast Cell-Specific Genes as New Drug Targets;195
18;Neuropeptide S Receptor 1: an Asthma Susceptibility Gene;207
19;Probiotics in the Treatment of Asthma and Allergy;222
20;Hypersensitivity Reactions to Nanomedicines: Causative Factors and Optimization of Design Parameters;239
21;An Environmental Systems Biology Approach to the Study of Asthma;252
22;Targeting Chemokine Receptors in Allergy;266
23;Dendritic Cell Vaccines;279
24;The Use of Microbes and Their Products in Allergy Prevention and Therapy;289
25;Targeting Insulin-Like Growth Factor-I in Allergen-Induced Airway Inflammation and Remodeling;302
26;Exosomes: Naturally Occurring Minimal Antigen-Presenting Units;315
27;Index;330